Our website uses cookies which are small bits of data stored as text files on your device. We use these cookies as described in our cookie policy. You can disable or change your cookie settings at any time but parts of our site will not function correctly without them.

IncyteCARES for Jakafi is a program for residents
of the United States and Puerto Rico.

Financial Assistance and Support
Options for Jakafi® (ruxolitinib)

Graphic of a Savings Card Graphic of a Savings Card Graphic of a Savings Card

IncyteCARES for Jakafi is committed to helping eligible patients get the medicine they need. That’s why we offer certain programs, and may be able to connect you to others, that may help make your out-of-pocket costs more affordable if you qualify. To qualify, you must meet certain eligibility requirements.

Savings card icon

For Eligible Patients With Commercial Prescription Insurance
IncyteCARES for Jakafi Savings Program

Eligible patients can receive Jakafi for as little as $0 per month*

Image of a IncyteCARES for Jakafi Savings card

To qualify, you must:

  • Have commercial prescription drug coverage. Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE—are not eligible. Patients without prescription drug coverage are also not eligible
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for Jakafi for an FDA-approved use

Amount of savings for the purchase of Jakafi will not exceed $11,977 per month and $25,000 per year. Uninsured, cash-paying patients are not eligible. Not valid for patients insured through Medicare Part D, Medicare Advantage, Medicaid, and TRICARE or any state medical or pharmaceutical assistance program. Valid prescription for Jakafi for an FDA-approved indication or compendia-recognized use is required. Please see full criteria for eligibility or call IncyteCARES for Jakafi at 1-855-452-5234. Update effective as of July 13, 2021.

Amount of savings for the purchase of Jakafi will not exceed $11,977 per month and $25,000 per year. Uninsured, cash-paying patients are not eligible. Not valid for patients insured through Medicare Part D, Medicare Advantage, Medicaid, and TRICARE or any state medical or pharmaceutical assistance program. Valid prescription for Jakafi for an FDA-approved indication or compendia-recognized use is required. Please see full criteria for eligibility or call IncyteCARES for Jakafi at 1-855-452-5234. Update effective as of July 13, 2021.

How to enroll:

Call IncyteCARES for Jakafi at 1-855-452-5234, Monday through Friday, 8 AM–8 PM ET.

We’ll ask you a few questions to determine your eligibility. If you are eligible, we can enroll you and get your program member number immediately. (A Savings Program card will also be mailed to you separately.) If you’d like, we can contact your specialty pharmacy to provide your program information so you can begin receiving Jakafi for as little as $0 per month right away.

You can also ask your Healthcare Professional or Specialty Pharmacist to enroll you in this Savings Program.

Hand and Rx symbol

For Eligible Patients Who Are Uninsured or Underinsured for Jakafi® (ruxolitinib)
IncyteCARES for Jakafi Patient Assistance Program

Eligible patients can receive Jakafi free of charge

The IncyteCARES for Jakafi Patient Assistance Program (PAP) helps eligible patients who do not have prescription drug insurance or have trouble affording their out-of-pocket costs for Jakafi. No purchase contingencies or other obligations apply.

To qualify, you must:

  • Be confirmed as eligible and enrolled in IncyteCARES for Jakafi
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for Jakafi for an FDA-approved use
  • Meet one of these 4 criteria:

    Uninsured with no coverage

    1. Meet certain household size and annual income criteria, including but not limited to earning less than $125,000 per year or less than 600% of the Federal Poverty Level (FPL), whichever amount is higher
    2. Underinsured

    3. Meet certain household size and income criteria, including but not limited to earning less than 600% of the FPL
    4. Commercially insured patients who have exhausted their benefit and have an inability to afford their medication or out-of-pocket costs
    5. Medicare Part D patients may be eligible by meeting additional criteria and program requirements, including but not limited to earning less than 600% of the FPL

The table below shows who might qualify for the Patient Assistance Program:

If this many people live in your household:

You may qualify if your full-year income before taxes is less than or equal to:

$77,280

104,520

131,760

159,000

186,240

If the patient lives in Alaska or Hawaii or has a household with more than 5 members, please call 1-855-452-5234. Income levels are subject to change on an annual basis; current levels reflect the 2021 Federal Poverty Level Guidelines.

How to apply:

Call IncyteCARES for Jakafi at 1-855-452-5234, Monday through Friday, 8 AM–8 PM ET.

To start, we’ll ask you a few questions to help determine your eligibility for this program. Based on your answers, we will notify you within 2 business days if you qualify for conditional approval. That means you’re approved for a supply of free medicine for 90 days. In the meantime, you must send us proof of your current household income. It can be one of the following: your most recent federal income tax return, your most recent W-2 earnings statement from your employer, or one month of your recent pay stubs. Once we review your income information, we’ll notify you if you are fully approved for the IncyteCARES for Jakafi Patient Assistance Program and can continue to receive Jakafi for free.

Terms and conditions apply. Terms of this program may change at any time.
clock icon

For Patients Whose Insurance Coverage Approval Is Delayed
IncyteCARES for Jakafi Temporary Access Program

Eligible patients may be able to receive a free short-term supply of Jakafi

If you have been prescribed Jakafi for an FDA-approved use and you experience a delay in coverage, we may be able to provide a free 30-day supply of medicine. No purchase contingencies or other obligations apply.

To qualify, patients must:

  • Be confirmed as eligible for and enrolled in IncyteCARES for Jakafi
  • Have commercial prescription drug coverage or a healthcare exchange plan. Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE—are not eligible. Patients without prescription drug coverage are also not eligible
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for Jakafi for an FDA-approved use
  • Provide proof of the submitted claim and coverage delay. This may be a notice you receive from your insurance company

To learn more:

Call IncyteCARES for Jakafi at 1-855-452-5234, Monday through Friday, 8 am–8 pm ET.

§Terms and conditions apply. Terms of this program may change at any time.
information icon

For All Patients
Information About Nonprofit or Other Support Organizations

Patients may be eligible for help with medicine, treatment-related travel, and other costs

If you do not qualify for our IncyteCARES for Jakafi Savings or Patient Assistance Programs, we may be able to provide information about other organizations or independent foundations that offer support. If you’re eligible, these independent organizations sometimes provide help with your medicine costs, transportation or lodging expenses related to treatment, or counseling services offered at reduced or no cost. Eligibility and availability of these programs are determined by the individual organizations.

To learn more:

Call IncyteCARES for Jakafi at 1-855-452-5234, Monday through Friday, 8 am–8 pm ET.

Image of Sue with text that says - Sue's Story. Click on the image to be taken to the video

Meet Sue and see how IncyteCARES for Jakafi
supports people
taking Jakafi.

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Jakafi is used to treat adults and children 12 years of age and older with chronic graft-versus-host disease (GVHD) who have taken one or two types of treatments and they did not work well enough.

IMPORTANT SAFETY INFORMATION

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, or white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.